At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 53 enrolled
Drug / intervention
alendronate sodium +1 moredrug
Likely dose
alendronate sodium 70 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal
In Brief
A Phase 4 clinical trial evaluating alendronate sodium and placebo comparator for Osteopenia and Osteoporosis. Completed, enrolled 53 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the changes in bone structure as determined by magnetic resonance imaging measurements among early postmenopausal women after 24 months of treatment with alendronate, 70 mg once a week as compared to placebo
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteopenia, Osteoporosis
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2006
First PostedJul 2007
Primary CompletionMar 2009
Study CompletionApr 2009
TodayJul 2026
First PostedJul 19, 2007
Enrollment StartFeb 1, 2006
Primary CompletionMar 1, 2009
Study CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 19.0 years ago
Interventions
alendronate sodiumdrug
alendronate sodium 70 mg tablet once week for 24 months
placebo comparatorother
placebo to match alendronate sodium one tablet once a week for 24 months